Amarantus is a biotechnology company focused on discovering and developing biologics to treat and/or diagnose Parkinson’s disease, Alzheimer’s disease, Traumatic Brain Injury, and other human diseases. The company has an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein it is developing to treat various protein folding-related medical conditions. For more information, visit the company’s website at www.amarantus.com.
Amarantus Bioscience Holdings, Inc. (AMBS) Starts Presentation at LD Micro Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option